Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
24-Feb-2026 | 326.75 | 326.75 | 318.45 | 320.55 | 9,639 | 5,79,59,020.3 | 73,791 |
25-Feb-2026 | 328 | 332 | 322.5 | 327.45 | 11,153 | 6,35,33,760.7 | 78,876 |
26-Feb-2026 | 327.45 | 344.5 | 327.45 | 339.75 | 25,171 | 27,13,29,667.55 | 3,79,741 |
27-Feb-2026 | 338 | 340.8 | 330.75 | 336.65 | 13,091 | 18,75,87,439.95 | 4,22,310 |
02-Mar-2026 | 315.9 | 334.05 | 315.9 | 323.55 | 10,269 | 7,59,02,071.8 | 1,02,781 |
04-Mar-2026 | 319.85 | 320.2 | 311.95 | 315.7 | 17,182 | 10,78,69,045.8 | 1,65,733 |
05-Mar-2026 | 318 | 328 | 318 | 323.8 | 12,290 | 6,75,64,447 | 1,08,711 |
06-Mar-2026 | 325.45 | 336.85 | 325 | 333.1 | 18,692 | 10,36,53,827.6 | 1,46,168 |
09-Mar-2026 | 329.8 | 335.7 | 316.75 | 333.15 | 17,242 | 12,44,14,553.25 | 1,86,835 |
10-Mar-2026 | 335 | 345.45 | 333.45 | 338.65 | 27,978 | 25,74,97,647.05 | 4,22,929 |
11-Mar-2026 | 340 | 348.25 | 334.15 | 336 | 23,528 | 25,21,12,209.25 | 4,28,889 |
12-Mar-2026 | 335.25 | 341.45 | 328.3 | 332.3 | 17,779 | 16,23,18,150.45 | 2,39,555 |
13-Mar-2026 | 334 | 335.6 | 312 | 312.8 | 17,673 | 11,72,16,347.7 | 2,03,222 |
16-Mar-2026 | 312.8 | 320 | 308.3 | 316 | 17,053 | 13,10,56,092.9 | 2,50,822 |
17-Mar-2026 | 320 | 322 | 314.4 | 317.9 | 10,146 | 7,15,95,981.95 | 1,30,143 |
18-Mar-2026 | 320.3 | 328.7 | 318.15 | 324.6 | 10,909 | 4,95,44,256.3 | 80,781 |
19-Mar-2026 | 315 | 325.55 | 312 | 314.75 | 11,426 | 7,47,20,579 | 1,31,249 |
20-Mar-2026 | 319 | 327.45 | 315.6 | 323.25 | 10,707 | 7,72,38,888.35 | 1,56,214 |
23-Mar-2026 | 320.15 | 320.4 | 311.05 | 312.35 | 11,441 | 7,87,37,395.25 | 1,45,545 |
24-Mar-2026 | 317 | 365 | 314.55 | 338 | 1,75,169 | 4,17,85,44,995.8 | 16,09,772 |
25-Mar-2026 | 338 | 352.65 | 337.65 | 345.3 | 39,477 | 36,20,96,892.1 | 4,15,347 |
It targets to initiate first-in-human clinical trials in patients with Essential Thrombocythemia and Polycythemia Vera.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Lodha Developers, Shilpa Medicare, etc.
USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
